-
Mashup Score: 67
In a pair of Special Reports, Gökbuget and colleagues present updated European Leukemia Net (ELN) consensus reports on (1) the diagnosis, prognostic factor
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 67
In a pair of Special Reports, Gökbuget and colleagues present updated European Leukemia Net (ELN) consensus reports on (1) the diagnosis, prognostic factor
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 27Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel - 9 hour(s) ago
In a pair of Special Reports, Gökbuget and colleagues present updated European Leukemia Net (ELN) consensus reports on (1) the diagnosis, prognostic factor
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 71Anaplastic Large Cell Lymphoma: Molecular Pathogenesis and Treatment - 20 hour(s) ago
Anaplastic large cell lymphoma (ALCL) is an uncommon type of non-Hodgkin’s lymphoma (NHL), as well as one of the subtypes of T cell lymphoma, accounting for 1 to 3% of non-Hodgkin’s lymphomas and around 15% of T cell lymphomas. In 2016, the World Health Organization (WHO) classified anaplastic large cell lymphoma into four categories: ALK-positive ALCL (ALK+ALCL), ALK-negative ALCL (ALK−ALCL), primary cutaneous ALCL (pcALCL), and breast-implant-associated ALCL (BIA-ALCL), respectively. Clinical symptoms, gene changes, prognoses, and therapy differ among the four types. Large lymphoid cells with copious cytoplasm and pleomorphic characteristics with horseshoe-shaped or reniform nuclei, for example, are found in both ALK+ and ALK−ALCL. However, their epidemiology and pathogenetic origins are distinct. BIA-ALCL is currently recognized as a new provisional entity, which is a noninvasive disease with favorable results. In this review, we focus on molecular pathogenesis and management of ana
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 71Anaplastic Large Cell Lymphoma: Molecular Pathogenesis and Treatment - 24 hour(s) ago
Anaplastic large cell lymphoma (ALCL) is an uncommon type of non-Hodgkin’s lymphoma (NHL), as well as one of the subtypes of T cell lymphoma, accounting for 1 to 3% of non-Hodgkin’s lymphomas and around 15% of T cell lymphomas. In 2016, the World Health Organization (WHO) classified anaplastic large cell lymphoma into four categories: ALK-positive ALCL (ALK+ALCL), ALK-negative ALCL (ALK−ALCL), primary cutaneous ALCL (pcALCL), and breast-implant-associated ALCL (BIA-ALCL), respectively. Clinical symptoms, gene changes, prognoses, and therapy differ among the four types. Large lymphoid cells with copious cytoplasm and pleomorphic characteristics with horseshoe-shaped or reniform nuclei, for example, are found in both ALK+ and ALK−ALCL. However, their epidemiology and pathogenetic origins are distinct. BIA-ALCL is currently recognized as a new provisional entity, which is a noninvasive disease with favorable results. In this review, we focus on molecular pathogenesis and management of ana
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 38ALK-negative anaplastic large cell lymphoma, leukemic phase - 1 day(s) ago
Shoot for 150-160 chars
Source: imagebank.hematology.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 71
Anaplastic large cell lymphoma (ALCL) is an uncommon type of non-Hodgkin’s lymphoma (NHL), as well as one of the subtypes of T cell lymphoma, accounting for 1 to 3% of non-Hodgkin’s lymphomas and around 15% of T cell lymphomas. In 2016, the World Health Organization (WHO) classified anaplastic large cell lymphoma into four categories: ALK-positive ALCL (ALK+ALCL), ALK-negative ALCL (ALK−ALCL), primary cutaneous ALCL (pcALCL), and breast-implant-associated ALCL (BIA-ALCL), respectively. Clinical symptoms, gene changes, prognoses, and therapy differ among the four types. Large lymphoid cells with copious cytoplasm and pleomorphic characteristics with horseshoe-shaped or reniform nuclei, for example, are found in both ALK+ and ALK−ALCL. However, their epidemiology and pathogenetic origins are distinct. BIA-ALCL is currently recognized as a new provisional entity, which is a noninvasive disease with favorable results. In this review, we focus on molecular pathogenesis and management of ana
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 26
Non-Hodgkin’s lymphomas (NHLs) are a heterogeneous group of lymphoproliferative disorders originating from B, T, or NK lymphocytes. They represent approximately 4–5% of new cancer cases and are classified according to the revised WHO system based on cell lineage, morphology, immunophenotype, and genetics. Diagnosis requires adequate biopsy material, though integrated approaches are used for leukemic presentations. Molecular profiling is improving classification and identifying prognostic markers. Indolent NHLs, such as follicular lymphoma and marginal zone lymphoma, typically pursue a non-aggressive clinical course with long survival. Aggressive diffuse large B-cell lymphoma (DLBCL) is the most common subtype. Recent studies have elucidated pathogenic mechanisms like MYC translocations and BCR pathway mutations. “Double hit” lymphomas with MYC and BCL2/BCL6 alterations confer a poor prognosis. Treatment approaches are evolving, with chemoimmunotherapy remaining standard for many indole
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 95
The treatment landscape of chronic lymphocytic leukemia (CLL), the most frequent leukemia in adults, is constantly changing. CLL patients can be divided into three risk categories, based on their IGHV mutational status and the occurrence of TP53 disruption and/or complex karyotype. For the first-line treatment of low- and intermediate-risk CLL, both the BCL2 inhibitor venetoclax plus obinutuzumab and the second generation BTK inhibitors (BTKi), namely acalabrutinib and zanubrutinib, are valuable and effective options. Conversely, venetoclax-based fixed duration therapies have not shown remarkable results in high-risk CLL patients, while continuous treatment with acalabrutinib and zanubrutinib displayed favorable outcomes, similar to those obtained in TP53 wild-type patients. The development of acquired resistance to pathway inhibitors is still a clinical challenge, and the optimal treatment sequencing of relapsed/refractory CLL is not completely established. Covalent BTKi-refractory pa
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 15
For patients with triple-class exposed/refractory multiple myeloma (TCE/RMM), where effective treatments options are limited, B-cell maturation antigen and CD3-directed bispecific antibodies offer …
Source: www.tandfonline.comCategories: General Medicine News, Hem/OncsTweet
Management of #ALL in adults: 2024 ELN recommendations from a European expert panel https://t.co/8rajb8llxe #leusm https://t.co/eCpGobVO3b